Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs

Antiviral Therapy

Volumn 10, Issue 4, 2005, Pages 469-477

  Boffito, Marta ^a,b   Acosta, Edward ^c   Burger, David ^d   Fletcher, Courtney V ^e   Flexner, Charles ^f   Garaffo, Rodolphe ^g   Gatti, Giorgio ^h,i   Kurowski, Michael ^j   Perno, Carlo Federico ^k   Peytavin, Gilles ^l   Regazzi, Mario ^m   Back, David ⁿ  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF COLORADO   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g PASTEUR HOSPITAL   (France)

^h VERTEX PHARMACEUTICALS   (United States)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j Therapia GmbH   (Germany)

^k UNIVERSITY OF ROME TOR VERGATA   (Italy)

^l BICHAT HOSPITAL   (France)

^m FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁿ UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR PHOSPHATE; ANTACID AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; CIDOFOVIR; DIDANOSINE; EFAVIRENZ; FLUINDOSTATIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOPINAVIR; METHADONE; MEVINOLIN; NELFINAVIR; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG;

ANOREXIA; AREA UNDER THE CURVE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG THERAPY; DRUG TOLERABILITY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IN VITRO STUDY; KIDNEY DISEASE; NAUSEA; PRIORITY JOURNAL; REVIEW; STOMACH PH; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG MONITORING; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 23044448423     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Piscitelli SC & Gallicano KD. Interactions among drugs for HIV and opportunistic infections. New England Journal of Medicine 2001; 344:984-996.
2. Kearney BP, Isaacson E, Sayre J, Namini H & Cheng A. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 533.
3. Rendon A, Barrios A, Gonzalez de Requena D, Maida I, Labarga P, Martin-Carbonero, Barreiro P, Garcia-Benayas T, Blanco F, Nunez M, Jimenez-Nacher I, Gonzalez-Lahoz J & Soriano V. Didanosine plasma levels in patients taking tenofovir concomitantly: high inter-individual variability but association with hyperlactatemia. HIV Medicine 2004; 5:233.
4. Reyataz® [atazanavir]. Summary of Product Characteristics. Bristol Meyer Squibb Company, Princeton, NJ, USA. July 2004.
5. Kruse G, Stocker H, Breske A, Arasteh K, Plettenberg A, Stazewski S & Kurowski M. Trough levels of six different atazanavir regimens in HIV-1 infected patients. 5th International Workshop on Clinical Pharmacology of HIV Therapy. 1-3 April 2004, Rome, Italy. Abstract 6.6.
6. DeJesus E, LaMarca A, Sension M, Beltran C & Yeni P. 24-Week efficacy & safety data of 908/r vs LPV/r in PI experienced subjects. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 178.
7. Kearney BP, Mittan A, Sayre J, Flaherty JF, Zhong L, Toole JJ & Cheng AK. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, IL, USA. Abstract A-1617.
8. Poirier J, Meynard J, Guiard-Schmid J, Girard P, Rozenbaum W & Jaillon P. Lack of alteration of lopinavir and ritonavir trough plasma concentrations in HIV-experienced patients treated with kaletra and tenofovir DF. 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy. 27-30 September 2002, San Diego, CA, USA. Abstract H-1715.
9. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clinical Pharmacokinetics 1999; 36:127-143.
10. Gutmann H, Fricker G, Drewe J, Toeroek M & Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Molecular Pharmacology 1999; 56:383-389.
11. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, Ronco P & Rossert J. Fanconi syndrome and renal failure induced by tenofovir: a first case report. American Journal of Kidney Diseases 2002; 40:1331-1333.
12. Coca S & Perazella MA. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. American Journal of Medical Sciences 2002; 324:342-344.
13. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M & Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17:935-937.
14. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F & Molina JM. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clinical Infectious Diseases 2003; 36:1070-1073.
15. Murphy MD, O'Hearn M & Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clinical Infectious Diseases 2003; 36:1082-1085.
16. Molla A, Mo H, Vasavanonda S, Han L, Lin CT, Hsu A & Kempf DJ. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrobial Agents & Chemotherapy 2002; 46:2249-2253.
17. Gonzalez-Garcia J, Carcas-Sansuan AJ & Duque B. Soft-gel saquinavir and lopinavir/ritonavir double boosted PI regimen: a pharmacokinetic study. 14th International AIDS Conference. 7-12 July 2002, Barcelona, Spain. Abstract B10398.
18. Ribera E, Diaz M, Pou L, Riuz L, Ruiz I, Ocana I & Falco V. Steady-state pharmacokinetics of double boosting regimen of lopinavir, plus minidose ritonavir, plus saquinavir soft-gel in HIV infected adults. 14th International AIDS Conference. 7-12 July 2002, Barcelona, Spain. Abstract TuPeB454.5.
19. la Porte CJ, Wasmuth JC, Schneider K, Rockstroh JK & Burger DM. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 2003; 17:1700-1702.
20. Smith GHR, Kline MB, Murphy T, Macleod JD, Routy JP, LeBlanc RP, Rene P, Gilmore N & Lalonde RG. Double boosted salvage therapy with lopinavir (LOP)/ritonavir (RIT) and saquinavir-sgc (SQR) in HIV-1 infected patients having failed 3 antiretroviral classes. 14th International AIDS Conference. 7-12 July 2002, Barcelona, Spain. Abstract TuPeB4547.
21. Zala C, Patterson P, Coll P, Bouzas MB, Kaufman S, Gun A, Perez H & Cahn P. Virological response and safety at 48 weeks of double boosted protease inhibitors with lopinavir/r plus either saquinavir or amprenavir in heavily pretreated HIV infected patients. 14th International AIDS Conference. 7-12 July 2002, Barcelona, Spain. Abstract TuPeB4492.
22. Hellinger J, Morris AB, Piscitelli S, Gordon D, Foy K, Jackson-Pope L, Cordeiro D, Peeters M, Hoetelmans R, de Caprariis PJ & Cohen C. Pilot study of saquinavir-sgc (Fortovase, SQV) 1000-mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor experienced HIV+ individuals: dose escalation and combined normalized inhibitory quotient (cNIQ). 9th Conference on Retroviruses & Opportunistic Infections. 24-28 February 2002, Seattle, WA, USA. Abstract 451-W.
23. Staszewski S, Dauer B, von Hentig N, Muller A, Stephan C, Carlebach A, Mosch M, Gute P, Klauke S, Kurowski M & Sturmer M. The LopSaq study: 24 week analysis of the double protease inhibitor salvage regimen containing lopinavir plus saquinavir without any additional antiretroviral therapy. 2nd IAS Conference on HIV Pathogenesis & Treatment. 13-16 July 2003, Paris, France. Abstract 583.
24. Stephan C, Hentig N, Kourbeti I, Dauer B, Mosch M, Lutz T, Klauke S, Harder S, Kurowski M & Staszewski S. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18:503-508.
25. Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG & Pozniak AL. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18:1291-1297.
26. von Hentig NH, Mueller A, Haberl A, Lutz T, Knecht G, Kurowski M, Harder S & Staszewski S. The ATSAQ-1 cohort study: pharmacokinetic interactions of atazanavir (AZV) and saquinavir (SQV) in a ritonavir (RTV) boosted protease inhibitor therapy regimen. 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract WeOrB1235.
27. Seminari E, Schira G, Guffanti M, Dorigatti F, Soldarini A, Gentilini L, Castagna A & Lazzarin A. Pharmacokinetics of saquinavir hard gel capsules when combined with atazanavir as once a day combination (1200/400) in highly experienced HIV-positive patients. 2nd IAS Conference on HIV Pathogenesis & Treatment. 13-16 July 2003, Paris, France. Abstract 847.
28. Canta F, Marrone R, Gonzalez de Requena D, Sciandra M, D'Avolio A, Bonora S, Veronese L, Caci A & Di Perri G. Pharmacokinetics of atazanavir (ATV) alone and coadministered with saquinavir hard gel (SQVhg) once daily. 5th International Workshop on Clinical Pharmacology of HIV Therapy. 1-3 April 2004, Rome, Italy. Abstract 4.21.
29. Badaro R, DeJesus E, Lazzarin A, Jemsek J, Clotet B, Rightmire A, Thiry A & Wilber R. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI on patients who have experienced virologic failure to multiple HAART regimens: 16-week results from BMS AI424-045. Antiviral Therapy 2003; 8(Suppl 1):S212.
30. Guffanti M, Villani P, Seminari E, Cusato M, Schira G, Danise A, Gianotti N, Lazzarin A, Castagna A & Regazzi M. Atazanavir (ATV) pharmacokinetics when combined with amprenavir (APV) in highly experienced HIV-positive patients. 5th International Workshop on Clinical Pharmacology of HIV Therapy. 1-3 April 2004, Rome, Italy. Abstract 4.10.
31. Guffanti M, De Pascalis CR, Seminari E, Fusetti G, Gianotti N, Bassetti D, Galli A, Castagna A & Lazzarin A. Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. AIDS 2003; 17:2669-2671.
32. Khanlou & Farthing C. Favourable interaction between atazanavir and fosamprenavir with and without ritonavir in the treatment of HIV-infected patients. 7th International Congress on Drug Therapy in HIV Infection. 14-18 November 2004, Glasgow, UK. Abstract P232.
33. Agenerase® [amprenavir]. Summary of Product Characteristics. GlaxoSmithKline, Research Triangle Park, NC, USA. February 2004.
34. Lexiva® [fosamprenavir]. Summary of Product Characteristics. GlaxoSmithKline, Research Triangle Park, NC, USA. May 2004.
35. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C & Polli JW. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metabolism & Disposition 2001; 29:754-760.
36. von Moltke LL, Durol AL, Duan SX & Greenblatt DJ. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. European Journal of Clinical Pharmacology 2000; 56:259-261.
37. Corbett AH, Eron JJ, Fiscus SA, Rezk NL & Kashuba AD. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. Journal of Acquired Immune Deficiency Syndromes 2004; 36:921-928.
38. Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B & Pozniak A. Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 2004; 37:1376-1384.
39. De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Hoetelmans RM & Cauda R. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. Journal of Acquired Immune Deficiency Syndromes 2004; 35:359-366.
40. Wynn Vezina HE, Brundage RC, Bushman L & Fletcher CV. Pharmacologic management of the drug-drug interaction between lopinavir/ritonavir and amprenavir. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 609.
41. Peytavin G, Lamotte C, Duval X, Matheron S, Boue F, de Truchis P, Reynes J, Katlama C & Farinotti R. Amprenavir (APV) plasma concentrations are dramatically decreased by the association with ABT378/r in HIV-infected patients (pts). 2nd International Workshop on Clinical Pharmacology of HIV Therapy. 2-4 April 2001, Noordwijk, the Netherlands. Abstract 1.14.
42. Fatkenheuer G, Romer K, Kamps R, Salzberger B & Burger D. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients. AIDS 2001; 15:2334-2335.
43. De Jesus E, LaMarca A, Sension M, Beltran C & Yeni P. The Context study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 178.
44. Meynard JL, Poirier JM, Guiard-Schmid JB, Morand-Joubert L, Jacquemet N, Rozenbaum W & Jaillon P. Impact of ABT378/r on the amprenavir (APV) plasma concentrations in HIV-experienced patients treated by the association APV-ABT378/r. 41st Interscience Conference on Antimicrobial Agents & Chemotherapy. 16-19 September 2001, Chicago, IL, USA. Abstract I-1736.
45. Le Tiec C, Barrail A, Vincent I, Chene G, Raguin G & Taburet AM. Pharmacokinetic parameters of amprenavir (APV), lopinavir (LPV), and ritonavir (RTV) when combined in HIV infected patients with multiple treatment failure. 3rd International Workshop on Clinical Pharmacology of HIV Therapy. 11-13 April 2002, Washington, DC, USA. Abstract 7.13.
46. Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir? AIDS 2002; 16:296-297.
47. Raguin G, Chene G, Morand-Joubert L, Taburet A, Droz C, Le Tiec C, Clavel F & Girard P. Salvage therapy with lopinavir/ritonavir (LPV/r), amprenavir (APV) ± an additional boost with ritonavir (RTV) in HIV infected patients (pts) with multiple treatment failure: final 26-week results of puzzle 1-ANRS104 study. 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy. 27-30 September 2002, San Diego, Ca, USA. Abstract H-1078.
48. Corbett AH, Davidson L, Park JJ, Patterson K, Eron JJ, Ngo L, Lim ML, Shelton M, Wire MB & Kashuba DM. Dose separation strategies to overcome the pharmacokinetic interaction of a triple protease inhibitor regimen containing fosamprenavir, lopinavir and ritonavir. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 611.
49. Wire MB, Naderer OJ, Masterman, AL, Lou Y & Stein DS. The pharmacokinetic interaction between GW433908 and lopinavir/ritonavir (APV10011 and APV 10012). 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 612.
50. Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR & Collier AC. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 2005; 19:145-152.
51. Klein C, Bertz R, Ashbrenner E, Chira L, Williams A, Hsu A & Bernstein B. Assessment of the multiple-dose pharmacokinetic interaction of lopinavir/ritonavir with nelfinavir. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 536.
52. Tseng A, Philips E, Antoniou T, Walker S, van Heeswijk R & Giguere P. Steady-state pharmacokinetics and tolerability of indinavir when co-administered with lopinavir/ritonavir in experienced subjects. 4th Workshop on Clinical Pharmacology of HIV Therapy. 27-29 March 2003, Cannes, France. Abstract 8.10.
53. Bertz RG, Foit C, Ashbrenner E, Horn P, Selness D, Berstein B, Chiu Y, Hsu A, Granneman R & Sun E. Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects. 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy. 27-30 September 2003, San Diego, CA, USA. Abstract A-1822.
54. Isaac A, Taylor S, Cane P, Smit E, Gibbons SE, White DJ, Drake SM, Khoo S & Back DJ. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. Journal of Antimicrobial Chemotherapy 2004; 54:498-502.
55. Casau NC, Gleshy MJ, Paul S & Gulick RM. Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2003; 32:494-498.
56. Gathe J, Khohlbrenner VM, Pierone G, Arasteh K, Rubio R, Lalonde R, Piliero P, McCallister S, Garfinkel S, Chaves R, Mukwaya GM, Dohnanyi C, Shaw S, Drees U & Mayers D. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 179.
57. Leith J, Walmsley S, Katlama C, Arasteh K, Pierone G, Blick G, Lazzarin A, Johnson M, Samuels C, Jones P, Quinson A, Kohlbrenner V, Mayers D, McCallister S & BI1182.51 study team. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV) amprenavir (APV), or lopinavir (LPV): Interim analysis of BI1182.51. 5th International Workshop on Clinical Pharmacology of HIV Therapy. 1-3 April 2004, Rome, Italy. Abstract 5.1.
58. Fichtenbaum CJ & Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clinical Pharmacokinetics 2002; 41:1195-1211.
59. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B & Aweeka F; NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-77.
60. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR & Sun E. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy 2003; 47:350-359.
61. Wire MB, Ballow C, Preston SL, Hendrix CW, Piliero PJ, Lou Y & Stein DS. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 2004 18:897-907.
62. Gerber JG, Fichtenbaum CJ, Rosenkranz S, Vega JM, Yang A, Alston B, Brobst SW, Segal Y, Aber JA & the ACTG A5108 team. Efavirenz is a significant inducer of simvastatin and atorvastatin metabolism: results of ACTG A5108 Study. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 603.
63. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Diseases 2003; 37:613-627.
64. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG & Back DJ. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. British Journal of Clinical Pharmacology 2001; 51:213-217.
65. Altice FL, Friedland GH & Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13:957-962.
66. Kurowski M, Pulik P, Kruse G, Stocker H, Arasteh K, Stanczak J, Higersherger J & Horban A. Pharmacokinetic interaction between efavirenz/abacavir and methadone in patients under directly observed treatment (DOT) and dosage adjustment over 60 weeks. 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract TuPeB4621.
67. Boffito M, Rossati A, Reynolds HE, Hoggard PG, Back DJ & Di Perri G. Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS Research & Human Retroviruses 2002; 18:341-342.
68. Mathews WC, McCutchan JA, Asch S, Turner BJ, Gifford AL, Kuromiya K, Brown J, Shapiro MF & Bozzette SA. National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. Medical Care 2000; 38:750-762.
69. Luber A, Garg V & Gharakhanain S. Survey medication used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART. 7th International Congress on Drug Therapy in HIV Infection. 14-18 November 2004, Glasgow, UK. Abstract P206.
70. Rublein JC, Donovan BJ, Hollowell SB, Min SS, Theodore D, Raasch RH & Kashuba ADM. Effect of omeprazole on the plasma concentrations of indinavir in HIV-negative subjects. Single dose 800 mg IDV. Cmin and AUC were similar to historical control when IDV administered with 200 mg RTV. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, IL, USA. Abstract A-1611.
71. BMS warning letter. REYATAZ® (atazanavir sulfate) with or without Norvir® (ritonavir) and proton pump inhibitors should not be coadministered: important new pharmacokinetic data. December 2004.
72. Ford SL, Wire MB, Lou Y, Baker KL & Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrobial Agents & Chemotherapy 2005; 49:467-469.
73. van Heeswijk R, Sabo JP, Cooper C, Cameron W, MacGregor TR, Elgadi M, Harris F, McCallister S & Mayers D. The pharmacokinetic interaction between tipranavir/ritonavir (500/200) bid and atorvastatin, antacid, and CYP3A4 in healthy adult volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy. 1-3 April 2004, Rome, Italy. Abstract 5.2.
74. Bertz RJ, Chiu YL, Naylor C, Luff K & Brun SC. Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. 7th International Congress on Drug Therapy in HIV infection. 14-18 November 2004, Glasgow, UK. Abstract P279.
75. Videx® [didanosine] chewable/dispersible buffered tablets. Summary of Product Characteristics. Bristol-Myers Squibb Company, Princeton, NJ, USA. January 2003.
76. Invirase® [saquinavir]. Summary of Product Characteristics. Roche, Welwyn Garden City, Hertfordshire, UK. September 2004.